Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like How Gilead's $12 Billion Kite Pharma Deal Has Already Paid Off for Investors September 18, 2017 MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate March 1, 2018 Medidata Solutions, Inc. Successfully Hosts Annual Conference Series July 12, 2017